- Publikační typ
- tisková chyba MeSH
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and the fourth most frequent cause of cancer-related death worldwide. Sorafenib is the first line recommended therapy for patients with locally advanced/metastatic HCC. The low response rate is attributed to intrinsic resistance of HCC cells to Sorafenib. The potential resistance to Sorafenib-induced cell death is multifactorial and involves all hallmarks of cancer. However, the presence of sub-therapeutic dose can negatively influence the antitumoral properties of the drug. In this sense, the present study showed that the sub-optimal Sorafenib concentration (10 nM) was associated with activation of caspase-9, AMP-activated protein kinase (AMPK), sustained autophagy, peroxisome proliferator-activated receptor-coactivator 1α (PGC-1α) and mitochondrial function in HepG2 cells. The increased mitochondrial respiration by Sorafenib (10 nM) was also observed in permeabilized HepG2 cells, but not in isolated rat mitochondria, which suggests the involvement of an upstream component in this regulatory mechanism. The basal glycolysis was dose dependently increased at early time point studied (6 h). Interestingly, Sorafenib increased nitric oxide (NO) generation that played an inhibitory role in mitochondrial respiration in sub-therapeutic dose of Sorafenib. The administration of sustained therapeutic dose of Sorafenib (10 µM, 24 h) induced mitochondrial dysfunction and dropped basal glycolysis derived acidification, as well as increased oxidative stress and apoptosis in HepG2. In conclusion, the accurate control of the administered dose of Sorafenib is relevant for the potential prosurvival or proapoptotic properties induced by the drug in liver cancer cells.
- Klíčová slova
- AMPK, Apoptosis, Autophagy, Mitochondria, Reactive oxygen species,
- MeSH
- autofagie účinky léků MeSH
- buněčná smrt účinky léků MeSH
- buňky Hep G2 MeSH
- chemorezistence účinky léků MeSH
- hepatocelulární karcinom metabolismus patologie MeSH
- jaterní mitochondrie účinky léků metabolismus MeSH
- kaspasa 9 metabolismus MeSH
- lidé MeSH
- nádory jater metabolismus patologie MeSH
- oxid dusnatý metabolismus MeSH
- potkani Wistar MeSH
- PPARGC1A metabolismus MeSH
- proteinkinasy aktivované AMP metabolismus MeSH
- protinádorové látky farmakologie MeSH
- signální transdukce účinky léků MeSH
- sorafenib farmakologie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- kaspasa 9 MeSH
- oxid dusnatý MeSH
- PPARGC1A protein, human MeSH Prohlížeč
- PPARGC1A MeSH
- proteinkinasy aktivované AMP MeSH
- protinádorové látky MeSH
- sorafenib MeSH
